Different behavioral effects of maprotiline and fluxilan in rats by Spasojević, Nataša et al.
INTRODUCTION
Stress has been implicated as a causative factor in the 
development of depression. It is known that norad-
renergic and serotonergic neurons originating from 
cell bodies in the brain stem ascend to many brain 
regions thought to be involved in some of the symp-
toms associated with depression. Serotonin and nor-
adrenaline are involved in the mechanisms of action 
of most antidepressant drugs and both mediate the 
antidepresant response, their effects being to some 
extent independent. Noradrenergic and serotoner-
gic antidepressants have been associated with some-
what different clinical effects. Noradrenergic anti-
depressants are thought to have prominent effects 
on motivation and drive, while antidepressants 
acting on serotonin are believed to have beneficial 
effects on anxiety and mood in depressed patients 
(M o n t g o m e r y, 1995, 1997). The neurochemi-
cal and behavioral effects of reduced central neu-
rotransmitter function and subsequent influence of 
antidepressants are difficult to study in humans for 
ethical reasons. Valuable tools for researching affec-
tive disorders are methods inducing depressive-like 
states in experimental animals. One of the frequent-
ly used approaches is the chronic unpredictable mild 
stress (CUMS) model of depression. Several animal 
models have been developed to evaluate putative 
antidepressants. Among these, the forced swim test 
(FST) proposed by P o r s o l t  and co-workers (1978) 
is a conventional model in which many antidepres-
sants reduce immobility, indicating that this is an 
index of antidepressant activity. However, there are 
few reports of differences between noradrenergic 
and serotonergic antidepressants in this test. In a 
number of studies, sertaline modified behavioral 
activity in the model (C e r v o  et al., 1991; K e l l y 
and L e o n a r  1994), while in another study sertra-
line, fluoxetine, and paroxetine were all reported 
to attenuate immobility times at moderate doses 
(D e t k e  et al., 1995). We i s s  and co-workers 
(1981) were the first to discriminate different forms 
of active behavior in the FST. They distinguished 
climbing and swimming. It was postulated that 
noradrenergic reuptake inhibitors promote strug-
DIFFERENT BEHAVIORAL EFFECTS OF MAPROTILINE AND FLUXILAN IN RATS 
NATAŠA SPASOJEVIĆ, LJUBICA GAVRILOVIĆ, and SLADJANA DRONJAK
Laboratory of Molecular Biology and Endocrinology, Vinča Institute of Nuclear Sciences, 11000 Belgrade, Serbia
Abstract — Serotonin and noradrenaline are involved in the mechanisms of action of most antidepressant drugs. We 
examined the effects of chronic treatment with maprotiline, a selective inhibitor of noradrenaline reuptake, and fluxi-
lan, a selective inhibitor of serotonin reuptake, on the behavior of unstressed controls and chronic unpredictable mild 
stress (CUMS) model rats in the forced swim test (FST) and elevated plus maze test. Both selective reuptake inhibitors 
resulted in a significant reduction of time spent in immobility. Climbing was significantly increased in maprotiline- and 
swimming was exclusively elicited in the fluxilan-treated unstressed control and CUMS rats. Maprotiline-treated ani-
mals displayed decreased anxiety and fluxilan-treated rats enhanced anxiety. The obtained results suggest that central 
noradrenergic and serotonergic systems might be affected differently during FST. The results also demonstrate that the 
anxiogenic effects of chronic fluxilan treatment are similar to those reported by many other studies. These differences 
observed for the effects of fluxilan in relation to those reported for maprotiline and probably due to the different phar-
macological profiles of these drugs.
Key words: Behavior, rats, antidepressants, monoamine reuptake inhibitors
UDC  577.25:591.481.8.087:615.214
33
Arch. Biol. Sci., Belgrade, 60 (1), 33-39, 2008                  DOI:10.2298/ABS0801033S
N. SPASOJEVIĆ ET AL.34
gling or climbing behavior, and that horizontal 
swimming is the behavioral manifestation of selec-
tive treatment with serotonin reuptake inhibitors. A 
number of studies of chronic antidepressant treat-
ment in the FST have been undertaken with vari-
able outcome, e.g., either unchanged or augmented 
behavioral responses relative to the standard acute 
treatment (B o r s i n i , 1995). The effects of antide-
pressants following chronic treatment have received 
little attention. Antidepressants acting on serotonin 
are thought to have beneficial effects on anxi-
ety in depressed patients (M o n t g o m e r y, 1995). 
This view was supported by the observation that 
such antidepressants appear to be effective across 
the spectrum of anxiety disorders, while in some 
anxiety disorders, noradrenaline antidepressants 
were not effective (D u b o v s k y, 1994). However, 
two studies reported that fluoxetine-treated animals 
displayed enhanced anxiety (S i l v a  et al., 1999; 
S h i s h k i n a  et al., 2006), while R o d g e r s  and 
co-workers (1997) recorded an anxiolytic-like effect 
with a low dose of maprotiline. 
The purpose of the present study was to examine 
the effects of chronic treatment with maprotiline, a 
selective inhibitor of noradrenaline reuptake, and 
fluxilan, a selective inhibitor of serotonin reuptake, 
in unstressed controls and CUMS rats, including 
detailed analyses of behavior to determine if reup-
take inhibitors selective for distinct monoaminer-
gicsystems produce exclusive behavioral responses.
METHODS
Animals
Adult Wistar rat males weighing 280 - 320 g at 
the onset of experiments and maintained in a tem-
perature-controlled room (21±1.0°C) under condi-
tions of a 12 h/12 h light/dark cycle were used.
Drugs and chronic treatment protocols
The rats were randomly divided into control 
(unstressed) and CUMS groups. These two groups 
were further divided into three subgroups each, the 
animals receiving daily injections of: 1. vehicle (ster-
ile water); 2. maprotiline (10 mg/kg); or 3. fluxilan 
(10 mg/kg) via the i.p. route. Exposure to CUMS 
and the vehicle, i.e., drug administration started 
on the same day and were continued for 4 weeks. 
Maprotiline (Sigma-Aldrich Chemie, Germany) and 
fluxilan (Aeigis LTD, Cyprus) solutions in sterile 
water sonicated for approximately 10 min were pre-
pared ex tempore. 
Chronic unpredictable mild stress (CUMS)
The CUMS procedure, a slight modification of 
the method described by G r i p p o  et al. (2002), 
was designed to maximize the unpredictable nature 
of the stressors. The CUMS groups were exposed to 
the following stressors in random order: continuous 
illumination (24 h), continuous darkness (24 h), 40º 
cage tilt along the vertical axis, crowding (eight rats 
per cage), soiled cage (300 ml water spilled onto the 
bedding), restraint in a small cage, cold room (4ºC), 
individual housing (24 h), forced running (15 min), 
and food and water deprivation. Animals were also 
maintained under conditions of a reversed light/dark 
cycle from Friday evening to Monday morning. 
Forced swim test procedure
This test is based on the orginal method of 
P o r s o l t  et al. (1978). Rats were transferred to 
individual cages 24 h before the first day of the 
two-day FST. On the first day of the experiment, 
the rats were plunged individually into a glass cyl-
inder (height, diameter: 35x24 cm) containing 20 
cm of water at 25 0C. Clean water was used for each 
behavioral trial, as use of water previously swum 
in by another rat has been shown to alter behavior. 
The animals were left to swim in the water for 15 
min before being removed, dried with paper towels, 
and returned to their home cage. Twenty-four hours 
later the procedure was repeated in a 5-min test 
session. The total times spent in each of the three 
behavioral classifications during the 5-min test ses-
sion were recorded. Instead of measuring the dura-
tion of the presence or absence of only immobility, 
the sampling procedure measures the frequency of 
behaviors over 5-s intervals during the test session. 
The behaviors measured were: immobility (i.e., 
floating and only making the movements necessary 
to keep the head above water); swimming (i.e., mak-
ing deliberate horizontal movements around the cyl-
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inder across the top of the water); and climbing (i.e., 
making intense movements with all four limbs, with 
the two forepaws either breaking the surface of the 
water or directed against the walls of the cylinder). 
Uncontrollable reflex movements during periods 
of immobility, such as shivering or wiping of water 
away from the eyes, were ignored. 
Elevated plus-maze procedure
The plus-maze consisted of two open arms, 50 
x 10 cm (length x width), and two enclosed arms, 
50 x 10 x 50 cm (length x width x height), arranged 
so that the two arms of each type were opposite to 
each other. The maze was elevated to a height of 50 
cm. The rats were placed individually in the center 
of the maze facing a closed arm and allowed 5 min 
of free exploration. The behavior of each animal 
in the maze was analyzed, taking into account the 
standard measures recorded in each section of the 
maze (closed and open arms, central platform), 
comprising the percent of open arm entries (arm 
entry defined as all four paws into an arm), total arm 
entries, and the percent of time spent by the animals 
in open arms of the maze. 
Statistics
Statistical analyses included the one-way ANOVA 
test. Data expressed as means ± SEM represent an 
average of eight animals. Statistical significance was 
accepted at p < 0.05.
RESULTS
The results presented in Table 1 show that 
vehicle-treated CUMS rats were characterized by 
significantly decreased climbing and swimming 
and increased immobility in comparison with the 
vehicle-treated unstressed control. There were sig-
nificant effects of treatment with both antidepres-
sants maprotiline (p<0.001) and fluxilan (p<0.01) 
- on immobility time. Both selective reuptake of 
inhibitors resulted in a significant reduction in 
time spent immobile in comparison with vehicle-
treated unstressed control and CUMS rats. Climbing 
was significantly increased in maprotiline-treated 
unstressed control and CUMS rats compared with 
the vehicle-treated groups. Administration of fluxi-
lan in the unstressed control and CUMS variants 
had no significant effect on climbing compared to 
the vehicle-treated groups. Swimming as a form 
of active behavior was exclusively elicited by the 
serotonin reuptake inhibitor fluxilan; as a result, the 
maprotiline-treated groups were identical to those 
of the vehicle-administered controls.
CUMS rats treated with the vehicle showed sig-
nificant (p<0.01) decrease of total arm entries, per-
centage of entries into open arms and time spent in 
open arms compared to vehicle-treated unstressed 
control rats. Maprotiline significantly increased the 
percentage of open arm entries in unstressed control 
(p<0.05) and CUMS (p<0.01) rats and increased 
the percentage of time spent in open arms in the 
unstressed control (p<0.001) and CUMS (p<0.05) 
variants. Animals treated with fluxilan in both the 
unstressed control and CUMS variants also dis-
played increase in each of the two parameters, but it 
was not statistically significant (Table 2).
DISCUSSION
Chronic stress has been found to affect different 
behavioral variables. We found that long-term social 
isolation in rats produces anxiety (S p a s o j e v i c 
et al., 2007). Chronic unpredictable mild stress, 
which has been used as a model of depression, 
was found to evoke various behavioral alterations, 
including increased immobility, decreased climb-
ing and swimming, and changes in anxiety-like 
behavior. In the present study, analysis of immobility 
revealed reductions caused by both selective reup-
take inhibitors, maprotiline and fluxilan, follow-
ing chronic treatment. Consistent with the present 
findings, C o n n o r  and co-workers (2000) did not 
find any changes in immobility after treatment with 
the serotonergic reuptake inhibitor paroxetine, but 
they observed that noradrenergic reuptake inhibitor 
desipramine significantly decreased immobility in 
the FST. Contradictory results can be attributed to 
different procedural approaches used in individual 
experiments. This is probably important in defining 
the role of brain monoamine neurotransmitters in 
depression. The results of C r y a n  and co-workers 
(2002) suggest that serotonin and noradrenaline are 
not ordinarily involved in mediating baseline stress-
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plus-maze test
Variable Total arm entries Percent open arm entries Percent open arm time
Unstressed control
+
vehicle
6,50 ± 0,76 18,67 ± 2,49 6,33 ± 1,05
CUMS
+
vehicle
##
2,00 ± 0,52
##
5,50 ± 1,18
##
1,16 ± 0,20
Unstressed control
+
maprotiline 7,50 ± 0,76
 *
30,83 ± 4,65
 ***
35,83 ± 4,41
CUMS
+
maprotiline 2,67 ± 0,42
**
17,16 ± 2,15
*
4,52 ± 1,08
Unstressed control
+
fluxilan 3,83 ± 0,60 24,50 ± 2,32 7,76 ± 0,99
CUMS
+
fluxilan
4,33 ± 0,49 7,67 ± 0,88 2,80 ± 0,66
Table. 1. Effect of chronic maprotiline and fluxilan treatment on immobility, climbing, and swimming behaviour sampled every 5 
sec during the 5-min FST. Data expressed as means ± SEM of nine rats. Statistical significance: # p<0.05; ### p<0.001 unstressed 
vehicle-receiving control vs. CUMS group receiving vehicle; ** p<0.01; *** p<0.001 maprotiline vs. vehicle; + p<0.05; ++ p<0.01; +++ 
p<0.001 fluxilan vs. vehicle.
Table. 2. Effect of chronic maprotiline and fluxilan treatment on total arm entries, the percentage of entries into open arms, and 
percentage of time spent in open arms of the elevated plus-maze. Data expressed as means ± SEM of nine rats. Statistical significance: 
## p<0.01 unstressed vehicle-receiving control vs. CUMS group receiving vehicle; * p<0.05; ** p<0.01; *** p<0.001 maprotiline vs. 
vehicle.
FST
Variable climbing immobility swimming
Unstressed control
+
vehicle
15,28 ± 1,30 20,87 ± 1,20 23,86 ± 1,60
CUMS
+
vehicle
 ###
8,17 ± 0,48
###
32,83 ± 2,85
 #
19,00 ± 1,10
Unstressed control
+
maprotiline
***
35,17 ± 1,72
 ***
5,00 ± 1,79 19,83 ± 2,43
CUMS
+
maprotiline
***
21,50 ± 0,85
 ***
26,00 ± 0,86
**
12,67 ± 1,17
Unstressed control
+
fluxilan 10,60 ± 0,87
++
15,60 ± 0,51
+++
33,80 ± 0,73
CUMS
+
fluxilan
8,25 ± 0,75 +++20,25 ± 0,85
 +
31,50 ± 3,77
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evoked performance, but do mediate changes in per-
formance produced by antidepressant treatments. 
The given neurotransmitters could be involved 
in augmenting immobility caused by stress, but 
this hypothesis has not been tested. E s p e j o  and 
M i n a n o  (1999) suggested dopaminergic media-
tion of the FST. They showed that prefronticortical 
dopamine lesions reduce overall immobility scores. 
The sequence of behaviors in the FST may be 
important for understanding the different functions 
of climbing and swimming. Climbing is ordinarily 
observed during the first minutes of the 5-min test, 
bouts of swimming occur throughout the inter-
val, and immobility is most frequent at the end of 
interval. Climbing and swimming appear to be two 
separate responses, linked sequentially in series, 
that facilitate escape during the FST. R e n e r i c  and 
L u c k i  (1998) as well as C r y a n  and co-work-
ers (2005) reported that climbing and swimming 
are exclusively evoked by selective noradrenergic 
and serotonergic reuptake inhibitors, respectively. 
In the present study, enhancement of climbing 
behavior appeared to be exclusively a product of 
noradrenergic reuptake inhibition, while augmen-
tation of swimming was exclusively the product 
of serotonergic reuptake inhibition. Because three 
serotonergic reuptake inhibitors - fluoxetine, ser-
traline, and paroxetine similarly evoked increased 
swimming in the FST, a serotonergic mechanism 
was inferred to mediate their behavioral activity 
(C r y a n  et al., 2005). Subsequently, it was shown 
that the swimming behavior produced by fluoxetine 
was prevented by pretreatment with the tryptophan 
hydroxylase inhibitor parachlorophenylalanine, but 
not the climbing behavior produced by the nor-
adrenaline reuptake inhibitor desipramine (P a g e 
et al., 1999). 
The obtained results suggest that central norad-
renergic and serotonergic systems might be affected 
differently during the FST. I z u m i  and co-wokers 
(1996) reported that stress induced by either han-
dling or saline injection increased the tissue content 
of noradrenaline as well as immobility in the tail 
suspension test in rats, whereas the tissue content of 
serotonin was not affected.
The elevated plus-maze is one of the most widely 
used animals models in contemporary preclinical 
research on anxiety (H a n d l e y  and M c B l a n e , 
1993; H o g , 1996; R o d g e r s  and C o l e , 1994). 
This model is based on the innate fear rodents have 
for open and elevated spaces. Stressed animals spent 
less time in open arms and more time in closed 
arms (Q i  et al., 2006). Evidence derived from clini-
cal studies suggests that antidepressant drugs can 
effectively treat anxiety disorders. Recent research 
has suggested that noradrenergic and serotoniner-
gic reuptake inhibitors are effective in this regard 
(N o w a k o w s k a  et al., 2000; K u r t  et al., 2000). 
However, preclinical investigations with serotoner-
gic reuptake inhibitors in animal models of anxiety 
disorders reveal highly variable effects of these 
drugs (S i l v a  et al., 1999). Our results show that 
chronic treatment with maprotiline increased the 
percentage of open arm entries and time spent in 
open arms, suggesting an anxiolytic effect. Chronic 
treatment with fluxilan did not change the percent-
age of open arm entries or time spent in open arms, 
suggesting an anxiogenic profile. These results could 
be connected with the data of S h i s h k i n a  and co-
workers (2006), who found that animals chronically 
treated with fluoxetine displayed enhanced anxiety 
and decreased locomotor activity. These differences 
observed for the effects of fluxilan in relation to 
those reported for maprotiline and probably due 
to the different distinct pharmacological profiles of 
these drugs. 
In conclusion, our results indicate that the 
anxiogenic effects of chronic fluxilan treatment are 
similar to those reported in many other studies. The 
lack of anxiolytic effects of chronic fluxilan treat-
ment also conforms with the poor efficacy of this 
drug in generalized anxiety disorders.
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РАЗЛИЧИТО ДЕЈСТВО МАПРОТИЛИНА И ФЛУКСИЛАНА НА ПОНАШАЊЕ ПАЦОВА
НАТАША СПАСОЈЕВИЋ, ЉУБИЦА ГАВРИЛОВИЋ и СЛАЂАНА ДРОЊАК
Лабораторија за молекуларну биологију и ендокринологију, Институт за нуклеарне науке "Винча", 
11001 Београд, Србија
Серотонин и норадреналин су укључени у 
механизам дејства већине антидепресива. Изуча-
вано је дејство хроничног третмана са мапроти-
лином, који је селективни инхибитор поновног 
преузимања норадреналина и флуксилана, селек-
тивног инхибитора поновног преузимања серото-
нина, на понашање код нестресираних контрола 
и пацова изложених хроничном непредвидивом 
благом стресу (CUMS), тестом пливања (FST) 
и тестом плус лавиринт платформе. Оба селек-
тивна инхибитора доводе до значајног смањења 
имобилности. Мапротилин доводи до повећаног 
пењања, док флуксилан изазива повећано плива-
ње,како код нестресираних контрола тако и код 
CUMS пацова током теста пливања. Животиње 
третиране са мапротилином показују смањење 
анксиозности, док пацови третирани са флукси-
ланом показују повећање анксиозности. Добије-
ни реултати указују да тест пливања може утица-
ти различито на централни норадренергички и 
серотонергички систем. Резултати такође показу-
ју да је анксиогено дејство хроничног третмана 
са флуксиланом слично са резултатима других 
студија. Уочене разлике између мапротилина и 
флуксилана су вероватно резултат различитог 
фармаколошког профила ова два лека.
